April 02, 2026
Dear Reader,
Vaccinology has always been a wager on our ability to outthink evolution. With Lyme borreliosis, the odds have long favored a shape-shifting spirochete and its Ixodes vector. New phase 3 data from the Pfizer/Valneva OspA-based vaccine suggest we may be closing that gap: a multivalent construct that matches the Borrelia ecology in North America and Europe, in an appropriately sized trial for relevant endpoints against the realities of vector-borne diseases. The results read, in part, as a quiet rebuttal to the legacy of LYMErix: the science was not the limiting factor.This issue stays briefly with Lyme disease in our infographic. We also examine hand, foot and mouth disease in Vietnam, where a fivefold early-year surge highlights the limits of hygiene in the absence of vaccination. The TBE snapshot from the Åland Islands considers early signals following the rollout of a general vaccination program.
In the news: World Immunization Week, Strategic Advisory Group of Experts on Immunization, polio’s persistent “emergency” status, and shifting U.S. schedule politics—all reinforcing a familiar conclusion: vaccines work; vaccination remains contested.
Enjoy the reading!
With best wishes for your continued health, and receive the vaccine doses you need.
Warm regards,
Editor-in-Chief, Global Health Press
 |
Your go-to source for concise
updates on the latest developments in the world of vaccines. This week's VacciNEWS viewpoint: |
 |
Infographic of the weekVacciTUTOR is our CME-accredited online course dedicated to vaccines and vaccination. Developed by leading international researchers, the course offers over 60 comprehensive chapters covering fundamental topics such as microbiology and immunology, as well as detailed insights into vaccine-preventable diseases and their corresponding vaccines. Concise bullet-point summaries are available free of charge to support quick reference and learning. Feel free to download today’s Lyme disease infographic. » |
|
The TBE snapshotSnapshot week 14/2026: Tick-borne encephalitis (TBE) cases in the Åland Islands have declined following the implementation of a general vaccination program. The data suggest that widespread vaccine uptake has reduced disease incidence, particularly in high-risk populations. However, cases have not been eliminated, indicating ongoing exposure risk from ticks. The findings highlight that while vaccination is highly effective in lowering TBE burden, continued surveillance and public awareness remain essential. |
Be part of the Global Health Press Community - id-ea.org
Join our GHP community and access exclusive, subscriber-only articles, expert reviews, and in-depth features. By becoming a subscriber, you’ll stay ahead of the news with the latest vaccines and vaccination updates. Enjoy content designed specifically for our engaged audience.
We’re also excited to welcome contributors who share our passion for advancing the field of vaccines and vaccination,
public health and education. Whether it’s submitting an article, serving as a Country Editor, contributing research,
or hosting a webinar, there are many ways to get involved.
Become part of the conversation and strengthen global health together with us. Subscribe and join today!
Contact us at info@globalhealthpress.org to learn more.
| Let’s get the word out! : | |
 |
|
| Like what you read? Forward this email to your friends or colleagues. | |
| Invite your friends |
At Global Health Press Pte Ltd, we are committed to safeguarding your privacy.
Your contact details are never shared with third parties. If you no longer wish to receive updates from us, you can unsubscribe here.
Copyright © 2009-2026 Global Health Press Pte Ltd. Reg. No. 200921795N